Financial News
Latest News about Phase 1 Trial
Recent news which mentions Phase 1 Trial
Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development
November 01, 2021
Tickers
MBIO
From Benzinga
Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial
October 27, 2021
Tickers
NRIX
From Benzinga
4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept
October 26, 2021
Tickers
FDMT
From Benzinga
Sio Gene Shares Gain As Genetic Nerve Cell Disorder Gene Therapy Trial Shows Encouraging Action
October 21, 2021
Tickers
SIOX
From Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
From Benzinga
Dermata Stock Jumps On Positive Psoriasis Candidate Data
October 19, 2021
Tickers
DRMA
From Benzinga
Vertex Unveils First Patient Results On Potential Diabetes Treatment
October 18, 2021
Tickers
VRTX
From Benzinga
Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting
October 11, 2021
Tickers
RPTX
From Benzinga
Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well
October 08, 2021
From Benzinga
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
October 07, 2021
Tickers
BCYC
From Benzinga
ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors
October 07, 2021
Tickers
ORIC
From Benzinga
Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?
October 07, 2021
Tickers
PRLD
From Benzinga
Amgen Highlights Lumakras Combination Data From Solid Tumor Trials
October 07, 2021
Tickers
AMGN
From Benzinga
4D Molecular To Test Its Wet AMD Gene Therapy In Patients
October 06, 2021
Tickers
FDMT
From Benzinga
Precigen Posts Additional Interim Data From Type 1 Diabetes Trial
October 01, 2021
From Benzinga
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
September 29, 2021
Tickers
EDIT
From Benzinga
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
September 29, 2021
From Benzinga
See Why Altimmune Stock Plunged After Obesity Trial Data
September 28, 2021
Tickers
ALT
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.